Evidence map›Paper›PMID 32590030›Full record

ArticleJournal of pharmaceutical sciences2021

Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.

Ruhul Kayesh, Taleah Farasyn, Alexandra Crowe, Qiang Liu, Sonia Pahwa, Khondoker Alam, Sibylle Neuhoff, Oliver Hatley, Kai Ding, Wei Yue

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ruhul KayeshDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Taleah FarasynDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Alexandra CroweDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Qiang LiuARL Bio Pharma, Oklahoma City, Oklahoma 73104.
Sonia PahwaDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Khondoker AlamDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Sibylle NeuhoffCertara UK Ltd, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ United Kingdom.
Oliver HatleyCertara UK Ltd, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ United Kingdom.
Kai DingDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Wei YueDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104. Electronic address: wei-yue@ouhsc.edu.
University of Oklahoma Health Sciences Center · USSimcyp (United Kingdom) · GBPure Protein (United States) · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
FV 10i-LIV Conofocal Imaging System (GM094268)R01GM094268 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI YUE, WEI · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA225520NIGMS NIH HHS R01 GM094268
6 · The paper itself

Abstract

Organic anion transporting polypeptides (OATP) 1B1 and OATP1B3 are important determinants of transporter-mediated drug-drug interactions (DDIs). Current studies assessed the OATP1B1 and OATP1B3-mediated DDI potential of vemurafenib, a kinase inhibitor drug with high protein binding and low aqueous solubility, using R-value and physiologically-based pharmacokinetic (PBPK) models. The total half-maximal inhibitory concentration (IC

Indexed as

Organic Anion TransportersDrug InteractionsHEK293 CellsHumansLiver-Specific Organic Anion Transporter 1Organic Anion Transporters, Sodium-IndependentSolute Carrier Organic Anion Transporter Family Member 1B3VemurafenibLiver-Specific Organic Anion Transporter 1Organic Anion TransportersOrganic Anion Transporters, Sodium-IndependentSolute Carrier Organic Anion Transporter Family Member 1B3VemurafenibDrug-drug interactionsKinase inhibitor drugOATP1B1OATP1B3Total IC(50) approachVemurafenib

Identifiers

PMID32590030
PMCPMC7750294
OpenAlexW3037273644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.